AzTrials
AzTrials

Irritable Bowel SyndromeNCT04921709

Renal Involvement in Inflammatory Bowel Disease Patients

An observational study of Irritable Bowel Syndrome, run by Assiut University at 1 site in Egypt.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

To evaluate renal involvement in inflammatory bowel disease patients . Read more about this study

Who is it for?
Ages 18 to 65 yearsHealthy volunteers can take part
Conditions the study is for
Irritable Bowel Syndrome
What is being tested?
Medical tests
How many people
60 participants
Where
1 siteEgypt
Study dates
1 Jun 2021to 1 Jan 2023
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: cohort study

Who may be able to join

  • patients with IBD diagnosed by colonoscopy and histopathology will classify the activity of the case to mild ,moderate and severe according to Mayo classification and have renal problems .
  • Age (18 - 65 years)

Who cannot join

  • patients underage of 18
  • HCV or HBV patients
  • renal patients diagnosed before diagnosis of IBD
  • diabetic or hypertensive patients
  • other autoimmune diseases such as Rheumatoid Arthritis, SLE.
  • Malignancy

Trial locations and contacts

1 site in 1 country.

Hend H Tawfik, Res contact

00201226253775

hend25793@gmail.com

Enas A Reda Alkaremy, Prof contact

00201000004303

Alkareemy@yahoo.com

Egypt1 site, 1 recruiting
  • Hend Hamdy Tawfik

    Minya

    Hend H Tawfik, Res, 00201226253775

    Recruiting

Other trials in Egypt

About this study

Official title: Evaluation of Renal Involvement in Inflammatory Bowel Disease Patients

To evaluate renal involvement in inflammatory bowel disease patients .

Read the detailed description

Inflammatory bowel disease (IBD) is a chronic, relapsing and remitting inflammatory condition predominantly affecting the gastrointestinal (GI) tract that results from complex interplay of the individual's genetic makeup, the environment, the gut microbiota and the host immune response .

IBD is an umbrella disorder that covers Crohn's disease, ulcerative colitis and IBD unclassified . Crohn's disease is characterised by transmural inflammation that can affect any part of the GIT with characteristic skip lesions of healthy tissues, while ulcerative colitis is a continuous mucosal inflammation largely confined to the colon. 'IBD unclassified' is a term used when the endoscopic and histological features are not sufficient to favour one of the other diagnoses.

The prevalence of extraintestinal manifestations (EIMs) in inflammatory bowel diseases (IBDs) varies from 6%-46%.

The mechanisms that have been suggested include contributions of genetic factors, infectious agents, circulating bacterial endotoxins and immune-complex deposition.

EIMs can involve almost every organ system. It is not always possible to identify the pathophysiological mechanism underlying an organ's involvement in IBD; it may originate from the same pathophysiological mechanism as intestinal disease, or as a secondary complication of IBDs, Renal involvement has been considered as an EIM and has been described both in Crohn's disease (CD) and in ulcerative colitis (UC).

Renal EIMs and IBD-related therapy are potential risk factors for the development of renal insufficiency (both acute and chronic) in patients with CD and UC.

Chronic kidney disease (CKD) is a type of kidney disease in which there is gradual loss of kidney function over a period of months to years.

CKD is defined as kidney damage or glomerular filtration rate (GFR) <60 ml /min/1.73 m2 for 3 months or more .

GFR can be estimated from calibrated serum creatinine and estimating equations ,such as the Modification of Diet in Renal Disease (MDRD) study equation or the Cockcroft -Gault formula .

Kidney disease severity is classified into five stages according to the level of GFR.

  1. Stage 1: Slightly diminished function; kidney damage with normal or relatively high GFR (≥90 ml/min/1.73 m2)
  2. Stage 2: Mild reduction in GFR (60-89 ml/min/1.73 m2) with kidney damage
  3. Stage 3: Moderate reduction in GFR (30-59 ml/min/1.73 m2)
  4. Stage 4: Severe reduction in GFR (15-29 ml/min/1.73 m2)
  5. Stage 5: Established kidney failure (GFR <15 ml/min/1.73 m2)

The most frequent renal diseases in patients with IBD are: nephrolithiasis, tubulointerstitial nephritis, glomerulonephritis and amyloidosis .

As in other EIMs, renal manifestations can be considered as dependent on the same immunological mechanism that determines intestinal inflammatory diseases, directly related to intestinal activity. Another hypothesis to be considered is that renal involvement is an independent of bowel disease, due to its autoimmune mechanism of action; otherwise, it could be related to metabolic disorders that develop in IBD. Finally, kidney pathologies in IBD have been associated with side e!ects of drugs Aminosalicylates, azathioprine, cyclosporin and TNFα inhibitors may be involved in renal impairment. However, it is not always possible to clarify the mechanism of these drugs in kidney damage. In many cases it remains unclear whether renal impairment is an EIM or a drug adverse effect

Being tested
Medical tests
Medical subject headings
Irritable Bowel Syndrome

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Medical testsOther

    Blood tests

Study groups in NCT04921709
Study groupRoleWhat they receive
IBD Patients with Renal Involvement1. Inclusion criteria: - patients with IBD diagnosed by colonoscopy and histopathology will classify the activity of the case to mild ,moderate and severe according to Mayo classification and have renal problems . Age (18-65 years) 2. Exclusion criteria: 1-patients underage of 18 2-HCV or HBV patients 3- renal patients diagnosed before diagnosis of IBD 4- diabetic or hypertensive patients 5- other autoimmune diseases such as Rheumatoid Arthritis, SLE. 6- Malignancy
Receives: Other: Medical tests
IBD Patients without Renal Involvement1. Inclusion criteria: - patients with IBD diagnosed by colonoscopy and histopathology will classify the activity of the case to mild ,moderate and severe according to Mayo classification and have no renal problems . Age (18-65 years) 2. Exclusion criteria: 1-patients underage of 18 2-HCV or HBV patients 3- renal patients diagnosed before diagnosis of IBD 4- diabetic or hypertensive patients 5- other autoimmune diseases such as Rheumatoid Arthritis, SLE. 6- Malignancy
Receives: Other: Medical tests

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. correlation between lab, radiological and colonoscopy

    All patients will be subjected to full clinical history , examination and investigation

    .investigations will include:

    A-Laboratory tests:

    • CBC
    • urine analysis
    • calculating the estimated glomerular filtration rate (eGFR)
    • 24hr urinary protein
    • hepatitis markers ,liver function tests
    • kidney function tests.
    • -kidney biopsy for patients with renal involvement if needed
    • ANA, Anti ds
    • blood electrolyte ( Na, K, Ca , Mg ) B- Radiological: abdominal ultrasonography C- colonoscopy . to evaluate renal ivolvement in inflammatory bowel disease

    Measured: Baseline

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted10 Jun 2021
  2. Study start1 Jun 2021
  3. Primary completion1 Oct 2022 (estimated)
  4. Study completion1 Jan 2023 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
60 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04921709
Sponsor's protocol ID
IBD impacts on kidney
Status last verified
Jun 2021
First submitted
3 Mar 2021
Last updated
10 Jun 2021
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Oikonomou K, Kapsoritakis A, Eleftheriadis T, Stefanidis I, Potamianos S. Renal manifestations and complications of inflammatory bowel disease. Inflamm Bowel Dis. 2011 Apr;17(4):1034-45. doi: 10.1002/ibd.21468. Epub 2010 Sep 14.

    PubMed 20842645
  • Pardi DS, Tremaine WJ, Sandborn WJ, McCarthy JT. Renal and urologic complications of inflammatory bowel disease. Am J Gastroenterol. 1998 Apr;93(4):504-14. doi: 10.1111/j.1572-0241.1998.156_b.x.

    PubMed 9576439
  • Yoo YJ, Chung SY, Gu DH, Ko GJ, Pyo HJ, Kwon YJ, Bak YT, Won NH. A case of late onset-acute tubulointerstitial nephritis with infliximab and mesalazine treatment in a patient with Crohn's disease. Korean J Gastroenterol. 2014 May;63(5):308-12. doi: 10.4166/kjg.2014.63.5.308.

    PubMed 24870303

Questions about this trial

What is this clinical trial studying?

An observational study of Irritable Bowel Syndrome, run by Assiut University at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 10 Jun 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Hend H Tawfik, Res (00201226253775, hend25793@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

correlation between lab, radiological and colonoscopy (time frame: Baseline). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04921709, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Jun 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in